Form 4: LeMaitre Vascular CEO Awarded Equity Compensation

LeMaitre Vascular's Chairman and CEO, George W. LeMaitre, received restricted stock units and stock options as part of his compensation package.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc. (LMAT), reported the acquisition of equity securities.
• Acquired 6,275 shares of Common Stock as a restricted stock unit (RSU) award on December 10, 2025, with a price of $0.
• Acquired 38,518 Stock Options (Right to Buy) with an exercise price of $83.66 on December 10, 2025.
• The RSU award vests 25% on December 1, 2026, with the balance vesting in equal annual installments over the subsequent three years.
• The stock options vest over a four-year period, with 25% vesting on the first anniversary of December 10, 2025, and the balance vesting in equal annual installments over the remaining three years.
• The stock options have an expiration date of December 10, 2032.
• Following these transactions, Mr. LeMaitre directly beneficially owns 1,670,105 shares of Common Stock and 38,518 Stock Options.
• An additional 21,300 shares of Common Stock are indirectly held by the LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025, for which Mr. LeMaitre disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation awards to the CEO, which is generally positive as it aligns management's interests with shareholders for long-term value creation. It does not contain any negative news or unexpected events.

Positives

• The grant of restricted stock units and stock options aligns the interests of the Chairman and CEO with those of shareholders, incentivizing long-term performance.
• Equity awards are a standard component of executive compensation, reflecting ongoing commitment to leadership.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a long-term incentive structure, with awards vesting over a four-year period. This suggests an expectation of continued leadership and performance from the Chairman and CEO.

Industry Context

The grant of equity compensation to a senior executive like the Chairman and CEO is a common practice in the medical device industry, aiming to align executive incentives with long-term shareholder value creation. This filing does not provide specific industry-wide comparative data but reflects standard corporate governance practices.

Comparison to Industry Standards

• Equity-based compensation, including restricted stock units and stock options, is a prevalent practice across the medical device sector and broader public markets for executive incentives.
• The four-year vesting schedule for both RSUs and options is typical for long-term incentive plans, comparable to structures seen at companies like Medtronic, Stryker, or Boston Scientific, which aim to retain talent and encourage sustained performance.

Related Party Transactions

• 21,300 shares of Common Stock are held indirectly by the LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025, which benefits the Reporting Person's child(ren). The Reporting Person disclaims beneficial ownership except for any pecuniary interest.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's incentives with shareholder interests, potentially leading to improved long-term performance. However, future share issuance upon vesting/exercise could lead to minor dilution.
• Employees: No direct impact on general employees is indicated, but executive compensation practices can influence overall company culture and compensation philosophy.
• Management: The awards provide significant long-term incentives for the Chairman and CEO, reinforcing retention and motivation.

Next Steps

• First tranche of restricted stock units will vest on December 1, 2026.
• Subsequent tranches of restricted stock units will vest annually over the following three years.
• First tranche of stock options will vest on December 10, 2026 (first anniversary of grant date).
• Subsequent tranches of stock options will vest annually over the following three years.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation awards to the Chairman and CEO. While these awards align management's interests with shareholders, they do not present new information that would significantly alter the fundamental investment thesis or warrant a strong buy or sell recommendation. It is a standard corporate governance event.

Keywords

LEMAITRE VASCULAR, LMAT, SEC Form 4, insider transaction, equity award, stock option, restricted stock unit, executive compensation, beneficial ownership